Fibrinogen Aα Thr312Ala Polymorphism Specifically Contributes to Chronic Thromboembolic Pulmonary Hypertension by Increasing Fibrin Resistance
Jifeng Li(Capital Medical University), Chen Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Na Cui(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuanhua Yang(Capital Medical University), Jie Liu(Capital Medical University), Jun Wang(Nanjing Drum Tower Hospital), Yan Liang(Capital Medical University), Yuan Lin(Capital Medical University), Lan Zhao(Fujian Medical University), Wei-Juan Zhang(Capital Medical University), Hui‐Li Gan(Capital Medical University), Suqiao Yang(Capital Medical University)
Cited by 36
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.7k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k